Lehman Brothers Global Healthcare Conference Lawrence S. Olanoff - MD, Ph.D President and Chief Operating Officer March 20, 2007
Safe Harbor Except for the historical information contained herein, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because these statements involve a number of risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, challenges relating to intellectual property protection, the impact of competitive products and pricing, the timely development and launch of new products and the risk factors listed from time to time in the Company s SEC reports, including the Company s Annual Report on Form 10-K for the fiscal year ended March 31, 20.
Strategically Focused Supporting growth of in-market products while building the pipeline to deliver long-term earnings performance License promising new products from innovative companies worldwide at virtually every stage of development Conduct rigorous and aggressive scientific development programs for drug therapies that can make a unique contribution to the field of healthcare and the lives of patients Execute focused marketing and sales initiatives to firmly establish our products in the marketplace
Feb- Jun- Oct- Feb-07 Oct-05 Jun-05 Feb-05 2,700 2,600 2,500 2,400 2,300 2,200 2,100 Core Business Strength Monthly Total Prescriptions (TRx,000) 550 475 400 325 250 175 100 Oct-04 Feb-05 Jun-05 Oct-05 Feb- Jun- Oct- Feb-07 Jun-04 Oct-04 1,200 1,100 1,000 900 800 700 600 500 Source: IMS Feb-07 Oct- Jun- Jun-04 Oct-04 Feb-05 Jun-05 Oct-05 Feb- Jun-04
Nov- Feb-07 14,500 14,000 13,500 13,000 12,500 12,000 11,500 11,000 SSRI Market Monthly TRx Volume 03 Δ 8.4% 04 Δ 2.8% 05 Δ -2.3% 03-Feb 03-MayAug-03 Nov-03 Feb-04May-04 Aug-04 Nov-04Feb-05 May-05 Aug-05Nov-05 Feb- May-Aug- SSRI TRx 3 Mo Av Avg. Δ 6.4%
SRI Market: Category Leadership in Detailing Detailing Investment ($,000) 14,000 12,000 Three Key Players 10,000 8,000 6,000 4,000 2,000 0 Jan- 05 Mar- 05 May- 05 Jul- 05 Sep- 05 Nov- 05 Jan- Mar- May- Jul- Sep- Nov- Jan- 07 LEXAPRO PAXIL+CR ZOLOFT CYMBALTA EFFEXOR/XR Source: IMS Integrated Promotional Services
Alzheimer s Market Growing Prevalence of Combination Therapy Network: Neurologist Mild Moderate Severe Namenda + AChE Inhibitor Combo Therapy Namenda Monotherapy AChE Inhibitor Monotherapy 16% 16% 16% 20% 18% 6% 7% 7% 4% 9% 11% 3% 41% 49% 44% 44% 47% 49% 62% 50% 73% 69% 62% 10% 8% 9% 9% 12% 9% 87% 12% 77% 77% 77% 76% 73% 10% 14% 2% 50% 42% 5% 10% 42% 42% 48% 47% 38% 30% 28% 24% 21% 21% n=142 126 140 112 89 119 389 333 386 325 277 370 69 58 56 61 63 64 69% Mar- Apr- May- Jun- Jul- Aug- Mar- Apr- May- Jun- Jul- Aug- Mar- Apr- May- Jun- Jul- Aug-
Aug- Nov- Feb-07 Monthly Market Share 35.00% 30.00% 25.00% 20.00% 15.00% 10.00% 5.00% 0.00% Feb-04 May-04 Aug-04 Nov-04 Feb-05 May-05 Aug-05 Nov-05 Feb- May- NRx Share TRx Share 32.9% N 32.4% T
Monthly NRx Share ARB + Combo Market 40% 35% 30% 25% 20% 15% 10% 5% 0% 7 th entry Feb- Jun- 03 03 Oct- 03 Feb- 04 Jun- 04 Oct- 04 Feb- 05 Jun- 05 Oct- 05 Feb- Jun- BENICAR + HCT COZAAR + HYZAAR DIOVAN+DIOVAN HCT Oct- Feb- 07 16.2% 3 rd in market share AVAPRO+AVALIDE ATACAND+ATACAND HCT MICARDIS+MICARDIS HCT Benicar is a registered trademark of Sankyo Pharma
Competitive Sales Force Ranked 14 th by Salesforce Size in US Source: Verispan 1 st Productivity 2 nd Forest 3 rd 4 th 5 th 2 nd Forest 1 st Sales Call Quality 2 nd 3 rd 4 th 5 th Forest 2 nd Forest Sensitivity to Time Constraints - GP 1 st 2 nd 3 rd 4 th 5 th Forest 2 nd Forest Unbiased Product Comparisons - GP 1 st 2 nd 3 rd 4 th Forest 4 th 5 th Forest
Ability to Compete Against Large Pharma Prozac (Eli Lilly) Zoloft (Pfizer) Paxil (Glaxo-SmithKline) Effexor (Wyeth) Cymbalta (Eli Lilly) Aricept (Pfizer) Exelon (Novartis) Razadyne (Johnson & Johnson) Diovan (Novartis) Cozaar (Merck) Avapro (Bristol-Myers Squibb)
Looking Forward
Licensing Criteria Late Phase Development Projects (Phase II POC and after) Opportunistic Individual Product Licenses/Acquisitions Co-Development and/or Co-Marketing Arrangements Follow-on Products from Established Partners Early Phase or Preclinical Projects (Pre-Phase II Results) Specific Therapeutic Targets of Interest Joint Venture or Portfolio Licensing Agreements Forest Development or Shared Development Discovery Projects/Target Identification (No Lead Candidate at Initiation)
Partner of Choice Products with potential peak sales of less than $1 Billion are attractive to Forest. Do not compete with our ex-us partners in their home markets, comfortable with both US-only or global license distribution agreements. We do not have a traditional drug discovery component that generates competitive drug candidates to partner projects. Partners can see Forest as their mirror image in terms of structure and size. Senior Management, including CEO, are involved in the deal agreement and in actively managing the project post agreement. No history of acquiring partners, whereas we frequently have the opportunity to review and sometimes license newly offered products from established partners.
The Forest Pipeline: Pre-Clinical/Phase I The Forest Pipeline Phase II Phase III NDA/sNDA mglur-5 for various CNS conditions ME1036 Broad spectrum carbapenem RGH-188 for schizophrenia and bipolar mania RGH-896 for chronic pain and other CNS conditions milnacipran for fibromyalgia ceftaroline for CAP, csssi Aclidinium for COPD Namenda QD for Alzheimer s disease nebivolol for hypertension Metabolic Target Lead project Obesity/Diabetes GRC-3886 (oglemilast) for COPD and asthma nebivolol- CHF neramexane for Alzheimer s disease desmoteplase for acute stroke Lexapro Pediatric indication
Pipeline: Key Initiatives Nebivolol Licensed January 11, 20 from Mylan Laboratories Novel beta blocker for hypertension Most highly selective beta blocker Has favorable differentiating characteristics, based on the Phase III studies Mylan Received FDA Approvable Letter May 31, 2005 Expect to submit response to Approvable Letter around the end of Fiscal Year 2007 Plans to submit a separate NDA for the treatment of congestive heart failure
Pipeline: Key Initiatives Milnacipran Dual Serotonin Norepinephrine Reuptake Inhibitor investigated for fibromyalgia (Cypress) Encouraging results from first Phase III Study: n=888 Predefined Primary Composite Endpoint which includes Pain and Patient Global Assessment yield p-value=0.058 LOCF analysis, Dropouts analyzed by BOCF yielded p-value=0.048. Enrollment in second Phase III study increased to 1,200 patients from 800 patients Topline Results to be reported during 2Q-calendar year 2007. Three-month endpoint. Ongoing discussions with FDA regarding analysis plan for second study Third Phase III Study enrolling targeted at 800 patients Significant market opportunity
Pipeline: Key Initiatives Ceftaroline Lead compound from acquisition of Cerexa, Inc. completed in January 2007 Broad-spectrum fifth generation Cephalosporin entering Phase III trials for csssi and CAP in 2007. (Active against MRSA) Injectable antibiotic for future sale by FRX Hospital Salesforce Hospital Infections kill 90,000/yr: excess costs of $4.5B (CDC est. WSJ 12/26/). Experienced antibiotic development team from Cerexa
Upcoming Clinical Data Topline Results 2007 2008 Milnacipran Second Phase III Study Desmoteplase DIAS 2 Memantine Phase III AD - MR RGH-188 Phase II Bipolar Mania Ceftaroline CSSSI- Phase III (2 Studies) RGH-188 Phase II Schizophrenia Lexapro Phase III Pediatric/Adolescent Depression Milnacipran Third Phase III Study Aclidinium - Phase III COPD (2 Studies)
Corporate Overview Lawrence S. Olanoff - MD, Ph.D President and Chief Operating Officer